PHARMATROPHIX - Key Persons
Anne Longo has been CEO of PharmatrophiX since 2010 and also serves as the Senior Director of Development for Neurology & Neurological Sciences at Stanford University. Following her graduation from Stanford University, she led programs at the NIH and at the Alliance for Aging Research in Washington DC. Ms. Longo also served in business development at Age Wave and at Charles Schwab in San Francisco. As CEO of PharmatrophiX, Ms. Longo develops and executes funding models, oversees finances working with the CFO, manages commercial projects and supervises contract research organization (CRO) projects. She has worked in medical development since March 2002 where she served as the Director of Development for the Department of Neurology at the University of North Carolina-Chapel Hill and then worked as the Director of Development at Stanford University for Women's Cancer and the Neurosciences beginning in May 2006. In her twenty-one years of medical development, Ms. Longo has raised over $250M in new gifts including 14 endowed medical school professorships.
Job Titles:
- Founding Director, Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada and Cleveland, Ohio
Jeffrey L. Cummings, MD, ScD, is Founding Director, Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada and Cleveland, Ohio. He is Professor of Medicine (Neurology), Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. He also serves as Principal Investigator/Director of the NIH/NIGMS-funded Center for Neurodegeneration and Translational Neuroscience. Dr. Cummings is a recognized world leader in Alzheimer's researcher and clinical trials. His many honors include the Henderson Award of the American Geriatrics Society (2006), the Ronald and Nancy Reagan Research Award of the national Alzheimer's Association (2008), and the Lifetime Achievement Award of the Society for Behavioral and Cognitive Neurology (2017). In 2010, he was honored by the American Association of Geriatric Psychiatry with their Distinguished Scientist Award. In 2018, he received the Leadership and Achievement Award by the International Society of CNS Drug Development and the Bengt Winblad Lifetime Achievement Award from the national Alzheimer's Association. He was featured in the Gentleman's Quarterly (June 2009) as a "Rock Star of Science."
John Autrey has been the CFO of PharmatophiX since 2008 providing accounting services, financial reporting, cash forecasting and NIH grant support to the management team and investors. Mr. Autrey works with PharmatrophiX's CEO on tax, insurance, banking, legal and other administrative issues. Mr. Autrey, based in Research Triangle Park, is a co-founder of Rankin McKenzie LLC, one of North Carolina's largest and most trusted financial management firms. He has extensive experience in assisting early stage companies and has served as the CFO for two medical device companies and two CROS. A North Carolina native, Mr. Autrey earned his Bachelor's degree from the University North Carolina - Chapel Hill and a Masters in Business Administration from Wake Forest University.
PharmatrophiX engages teams of advisors consisting of senior industry and academic experts in all
stages of drug development and in global strategies and approaches in Alzheimer's and
Lon Schneider, MD, serves as Director of the USC National Institute on Aging Alzheimer's Disease Research Center clinical core and the USC State of California Alzheimer's Disease Center. His advisory roles have included senior scientific advisor at the NIMH, on the American Psychiatric Association Committee for Practice Guidelines in Alzheimer's and Other Dementia, the World Federation of Societies of Biological Psychiatry Task Force on Dementia. He holds a master's degree in biometry and epidemiology and is a widely sought expert in clinical trials methods and drug development. His work involves development with novel neuroregenerative disese therapeutics, the science of outcomes assessment, and approaches to modeling and clinical trials simulations. He is an associate editor or editorial board member of several publications, including the Cochrane Dementia and Cognitive Improvement Group, Current Alzheimer Research, BMC-Psychiatry, Alzheimer's & Dementia, The Lancet Neurology, and Clinical Neuropharmacology among others. He serves as editor-in-chief of Alzheimer's & Dementia: Translational Research and Clinical Interventions; and has authored numerous papers and chapters.